An interventional study of EXERCISE TRAINING and Antiresorptive medication (routine clinical care) in Osteoporosis in Post-menopausal Women, sponsored by Loughborough University. Not yet recruiting at 1 site in United Kingdom. Open to female participants aged 55 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-05.
Sponsored by Loughborough University · Not applicable, Interventional, and Prevention
Osteoporosis is a systemic bone disorder characterised by a reduced bone mass and structural deterioration, increasing the risk of fragility fractures, particularly in women post-menopause. Bone mass and structure can be assessed by scans.
Antiresorptive medications are commonly prescribed to reduce bone resorption, preventing further bone loss and thus reducing the possibility of fracture. Exercise can also benefit bone mass and structure but current evidence do not show whether exercise is more, or less, effective in combination with antiresorptive medication.
This study will compare the effect of a brief, home-based exercise programme on bone mineral and structural properties in women taking/ not taking antiresorptive medication.
Exercise can benefit bone density and induce structural changes, leading to a decrease in fracture risk. High-impact exercise is often recommended for promoting bone health as it generates the brief, high strains that stimulate bone adaptation. Brief multidirectional hopping exercises have been demonstrated to be a practical and sustainable intervention with older men, pre- and postmenopausal women. They allow exercise to be conducted on one leg, whilst changes in the other leg can be used as a control to compare what would happen without exercise.
The effects of exercise on bone density and structure may be different in women taking osteoporosis medication, but few studies have examined this group. This study thus aims to evaluate the effects of exercise on bone density and structure according to osteoporosis medication use.
The study will be a 12-month long randomised controlled trial including two groups: with and without antiresorptive osteoporosis medication for at least 12 months. Participants must not plan to change their treatment choices during the 12-month study. All participants will complete a 12-month unilateral hopping exercise intervention.
Screening and baseline measurements will include dual X-ray absorptiometry (DXA) and computed tomography (CT) scans of the hip, blood collection, hop assessment and questionnaires. Eligible participants will then be invited to commence the exercise intervention and randomly allocated an exercise leg, with the contralateral leg being untrained to provide a control leg. Randomisation of exercise and control legs will be performed by selecting an opaque sealed envelopes which contain "R" or "L" letters. It is not possible to blind the participant or researchers supervising the intervention to leg allocation.
An initial familiarisation session will be conducted under supervision. The exercise intervention involves a home-based exercise programme starting at three days per week, with the goal of increasing to seven days per week. It will begin with a warm-up targeting the legs and lower back, followed by a progressive exercise regimen that will gradually increase in technique, intensity, and frequency to ensure safety. It will be personalised according to the participants' physical abilities and responses during or after the exercise. Weekly supervised group sessions will be offered, and used to advise participants on progression of exercise. An exercise logbook will monitor adherence. A questionnaire on any injuries, soreness, or discomfort will be administered monthly online or by phone. Participants will be instructed to reduce intensity and frequency or discontinue exercise if they experience any adverse symptoms or discomfort.
Follow-up measurements will be conducted six and twelve months after the start of the exercise intervention is completed. All measurements , except for the CT scan, will also be repeated after six months with each visit expected to last no more than two hours. whereas at twelve months, all measurements will be repeated. CT scans will take place at Glenfield Hospital, Leicester. All other visits will take place at Loughborough University.
Have no regular involvement for more than once/week in:
Exclusion Criteria:
Participants in this arm are postmenopausal women with low bone density who are not taking any bone medication for at least 12 months. They will participate in a 12-month supervised high impact unilateral hopping exercise.
Behavioral: EXERCISE TRAINING
Participants in this arm are postmenopausal women with low bone density who are taking antiresorptive medication for at least 12 months. They will participate in a 12-month supervised high impact unilateral hopping exercise.
Behavioral: EXERCISE TRAINING · Drug: Antiresorptive medication (routine clinical care)
The unilateral high-impact (hopping) exercise will be on one randomly allocated exercise leg, with the contralateral leg being untrained to provide a control leg. Each session will begin with a warm-up targeting the legs and lower back. The progressive exercise regimen consists of multidirectional hopping exercises that will gradually increase in technique, intensity, and frequency to ensure safety. It will be personalised according to the participants' physical abilities and responses during or after the exercise.
Participants in this arm are already taking prescribed antiresorptive medication as part of standard clinical care. The study will not provide or modify the medication.
Femoral neck bone mineral content BMC
(g) measured by DXA
Time frame: Baseline, 6 months and 12 months
Femoral neck bone mineral density BMD
(g/cm\^2) measured by DXA
Time frame: Baseline, 6 months and 12 months
Total hip bone mineral content BMC
(g) measured by DXA
Time frame: Baseline, 6 months and 12 months
Total hip bone mineral density BMD
(g/cm\^2) measured by DXA
Time frame: Baseline, 6 months and 12 months
Lumbar spine bone mineral content BMC
(g) measured by DXA
Time frame: Baseline, 6 months and 12 months
Lumbar spine bone mineral density BMD
(g/cm\^2) measured by DXA
Time frame: Baseline, 6 months and 12 months
Prevalent vertebral fracture
assessed using DXA vertebral morphology
Time frame: Baseline, 6 months and 12 months
Whole body composition
weight in Kg
Time frame: Baseline, 6 months and 12 months
Whole body composition
Hight in cm
Time frame: Baseline, 6 months and 12 months
Total fat mass
will be measured using whole body DXA, reported in Kg
Time frame: Baseline, 6 months and 12 months
Lean mass
will be measured using whole body DXA, reported in Kg
Time frame: Baseline, 6 months and 12 months
Tibia distal (4%) Total volumetric bone density vBMD
(mg/cm\^3) measured by pQCT
Time frame: Baseline, 6 months and 12 months
Tibia distal (4%) trabecular density vBMD
(mg/cm\^3) measured by pQCT
Time frame: Baseline, 6 months and 12 months
Tibia distal (4%)Total bone area
(mm) measured by pQCT
Time frame: Baseline, 6 months and 12 months
Tibia shaft (66%) cortical content per 1 mm
(mg/mm) measured by pQCT
Time frame: Baseline, 6 months and 12 months
Tibia shaft (66%) cortical thickness
(mm) measured by pQCT
Time frame: Baseline, 6 months and 12 months
Tibia shaft (66%) cortical vBMD
(mg/cm\^3) measured by pQCT
Time frame: Baseline, 6 months and 12 months
Femoral neck integral BMC
g measured by QCT
Time frame: Baseline and 12 months
Femoral neck cortical BMC
g measured by QCT
Time frame: Baseline and 12 months
Femoral neck trabecular BMC
g measured by QCT
Time frame: Baseline and 12 months
Proximal femur cortical thickness
mm measured by QCT
Time frame: Baseline and 12 months
Plasma bone turnover biomarkers (resorption marker)
Bone turnover will be assessed using blood samples to measure C-terminal telopeptide of type I collagen (CTX) which will be reported in µg/L where higher values reflect higher bone turnover, which is associated with increased bone loss
Time frame: Baseline, 6 months and 12 months
Hop performance (ground reaction force).
measured by force plate reported in Newtons (N)
Time frame: Baseline, 6 months and 12 months
Total Bone-specific Physical Activity Questionnaire (BPAQ) score
Total score from the Bone specific Physical Activity Questionnaire will be calculated based on physical activity, intensity and frequency The questionnaire does not have a fixed minimum or maximum score, and values depend on each participant's activity history. Higher scores indicate higher levels of bone loading physical activity. The contribution of this activity to skeletal adaptation.
Time frame: Baseline and 12 months
Daily calcium intake
(mg) Calcium Questionnaire
Time frame: Baseline, 6 months and 12 months
Fall and balance confidence
will be assessed using Short Falls Efficacy Scale International (short- FES-I). The scale includes 7 items, each scored from 1 (Not at all concerned) to 4 (Very concerned). Total scores range from 7 to 28, where higher scores indicate lower confidence and greater fear of falling.
Time frame: Baseline, 6 months and 12 months
Trochanter BMD
g/cm\^2 by DXA
Time frame: Baseline, 6month and 12month
Trochanter BMC
g by DXA
Time frame: Baseline, 6month and 12month
Tibia shaft (66%) cortical area
(mm\^2) measured by pQCT
Time frame: Baseline, 6 months and 12 months
Tibia shaft (66%) Periosteal circumference
(mm) measured by pQCT
Time frame: Baseline, 6 months and 12 months
Tibia shaft (66%) Endosteal circumference
(mm) measured by pQCT
Time frame: Baseline, 6 months and 12 months
Tibia shaft (66%) Axial area moment of inertia
(mm\^4) measured by pQCT
Time frame: Baseline, 6 months and 12 months
Tibia shaft (66%) Moment of resistance
(mm\^3) measured by pQCT
Time frame: Baseline, 6 months and 12 months
Tibia shaft (66%) Total bone area
(mm\^2) measured by pQCT
Time frame: Baseline, 6 months and 12 months
Tibia shaft (66%) Strength Strain Index
(mm\^3) measured by pQCT
Time frame: Baseline, 6 months and 12 months
Trochanter integral BMC
g measured by QCT
Time frame: Baseline and 12 months
Trochanter cortical BMC
g measured by QCT
Time frame: Baseline and 12 months
Trochanter trabecular BMC
g measured by QCT
Time frame: Baseline and 12 months
Intertrochanter integral BMC
g measured by QCT
Time frame: Baseline and 12 months
Intertrochanter cortical BMC
g measured by QCT
Time frame: Baseline and 12 months
Intertrochanter trabecular BMC
g measured by QCT
Time frame: Baseline and 12 months
Mid-femoral neck geometry
Buckling ratio measured by QCT
Time frame: Baseline and 12 months
Mid-femoral neck geometry
Cross-sectional moment of inertia minimum (cm\^4) measured by QCT
Time frame: Baseline and 12 months
Mid-femoral neck geometry
Cross-sectional moment of inertia maximum (cm\^4) measured by QCT
Time frame: Baseline and 12 months
Mid-femoral neck geometry
Cross-sectional moment of area (cm\^2) measured by QCT
Time frame: Baseline and 12 months
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Loughborough University